Lightnews — Scholar-powered news

MedChemica

@medchemica.com

33 followers 5 following 6 posts

We supply knowledge based design and analysis software to help our clients focus on making the best compounds quickly. Our consulting services in medicinal chemistry and cheminformatics help your projects large or small move faster.

Posts Media Videos Starter Packs

MedChemica @medchemica.com · Jun 10

New OpenBind consortium to make the UK a leader in AI-driven drug discovery-slashing the cost of drug discovery & development.. & MedChemica are at the heart of it!
Click for the full gov.uk article and direct quote from our Technical Director @griffen-ed.bsky.social
www.gov.uk/government/n...

Reposted by MedChemica

Sébastien Morin @sebmoringva.bsky.social · Apr 10

Interesting piece from colleagues at @dndi.org and @medchemica.com on maximizing the potential for broad #access to #medicines being developed as #public #goods
—
#GlobalHealth #Equity #IP #Patents #Licensing
—
cen.acs.org/pharmaceutic...

Opinion: How patents can serve the common good

We want wide, fast, and affordable access for our new antiviral. It might sound counterintuitive, but a patent will help us do that

cen.acs.org

1 2

Reposted by MedChemica

The ASAP Discovery Consortium @asapdiscovery.bsky.social · Mar 21

Lead medicinal chemist Ed Griffen (@griffen-ed.bsky.social) will be disclosing the new ASAP MERS-CoV/SARS-CoV-2 oral antiviral at @acs.org on Tue 25 Mar! Tune in to this virtual session to hear about its discovery and development!

acs.digitellinc.com/live/34/sess...

ACS talk 4181593 - Discovery of non-peptidomimetic oral combined MERS and SARS-CoV-2 anti-virals

Presented by Ed Griffen

Part of the session "Developing Countermeasures for Viruses of Pandemic Potential"

Room: Digital Session (Digital Meeting)

Overview:

The COVID-19 pandemic was a stark reminder that a barren global antiviral pipeline has grave humanitarian consequences. Pandemics could be prevented, in principle, by accessible, easily deployable broad-spectrum oral antivirals. Here we report the discovery of a family non-peptidomimetic spirolactams that target critical pathogenic coronaviridae including SARS-CoV-2 and MERS-CoV.
As part of the ASAP AViDD centre(www.asapdiscovery.org) we expanded the work of the COVID Moonshot's drug discovery campaign targeting the SARS-CoV-2 main protease to deliver orally active compounds with promising in vivo profiles. Using a combination of active learning based medicinal chemistry, alchemical free energy calculations and structure-based design we were able to extend the coronavirus spectrum and optimise the ADMET properties of the series leading to the first public disclosure of the preclinical candidate.

6 13

Reposted by MedChemica

Drugs for Neglected Diseases initiative (DNDi) @dndi.org · Mar 25

1 4

Reposted by MedChemica

Drugs for Neglected Diseases initiative (DNDi) @dndi.org · Mar 25

📢Important announcement! Today, the @asapdiscovery.bsky.social consortium disclosed the structure of our preclinical candidate, ASAP-0017445, a promising broad-spectrum antiviral with potent activity against SARS-CoV2 and other viruses belonging to the same family. (1/10)

3 22 51

MedChemica @medchemica.com · Mar 5

5 weeks to go🚀

@griffen-ed.bsky.social is presenting at the @conscience-network.bsky.social Symposium. Talk Title; "Balancing Open Science and Intellectual Property to Discover and Develop Medicines” @asapdiscovery.bsky.social

Register now: conscience.ca/symposium202...

3 3

MedChemica @medchemica.com · Feb 27

5 weeks to go! 🚀
Dr @griffen-ed.bsky.social is presenting at the ACS Spring Meeting & Expo. Talk Title; “Discovery of non-peptidomimetic oral combined MERS and SARS-CoV-2 anti-virals." @asapdiscovery.bsky.social @acs.org #ACSSpring2025

Click to register 🔗 www.acs.org/meetings/acs...

2 1

MedChemica @medchemica.com · Feb 25

3 weeks to go🚀
@griffen-ed.bsky.social is presenting at #ICAR2025 the highlights of the discovery, in vitro and in vivo profile of the ASAP AViIDD Center’s pre-clinical candidate for treating 6 lethal coronavirus infections: ASAP-0017445. Register now 🔗 lnkd.in/gbBRZSz2 @asapdiscovery.bsky.social

1 1

MedChemica @medchemica.com · Feb 18

Who is attending the 'Chemist In Industry' SCI conference at Alderley Park tomorrow? Our very own Dr @aldossetter.bsky.social is presenting an insightful talk on ‘Addressing ‘The Big Two.’ – Intrigued? You should be!
See you all there!

#SCI #ChemistInIndustry #DrugDiscovery #DrugDesign

Reposted by MedChemica

Conscience @conscience-network.bsky.social · Feb 17

@thesgc.bsky.social @medchemica.com @asapdiscovery.bsky.social

1 1

MedChemica @medchemica.com · Nov 20

Don't miss our very own Dr Ed Griffen @griffen-ed.bsky.social giving a talk today at the AViDD Open Science Forum...

The ASAP Discovery Consortium @asapdiscovery.bsky.social · Nov 20

Tune in Wed 20 Nov at 11A ET for our Antiviral Drug Discovery Open Science Forum to hear Ed Griffen (@griffen-ed.bsky.social) [MedChemica @medchemica.bsky.social] and Pascale Boulet [DNDi @dndi.bsky.social] discuss enabling affordable access with creative IP agreements!

asapdiscovery.org/forum/

Antiviral Drug Discovery (AViDD) Open Science Forum

A public venue to enable NIH-funded AViDD Centers to openly exchange and disseminate information in a pre-competitive fashion.

asapdiscovery.org